Tag: Timothy Miller December 22, 2025 New drug may slow progression of ALS in small group of patients: StudySource: ABC News December 22, 2025 New ALS drug stabilizes decline with improved strength, mobility for someLong-term use of tofersen slows ALS disease progression in people with a genetic subtype, provides hope for treating other forms of ALS.News Release October 9, 2023 Avidan, England, Miller elected to National Academy of MedicineMembership is one of highest U.S. honors in health and medicine.News Release April 25, 2023 Drug for rare form of ALS, based in part on WashU research, approved by FDAWashington University neurologist led international trials of the drug, tofersen.News Release, Video February 2, 2023 Miller receives Rainwater Prize for Brain ResearchHonored for work developing new kind of therapy for neurodegenerative diseases.National Leaders September 21, 2022 Investigational drug for genetic form of ALS improves disease’s molecular signsExtended use of tofersen may help stabilize muscle strength, control.News Release July 8, 2020 Experimental drug shows early promise against inherited form of ALS, trial indicatesPhase 1/phase 2 trial shows evidence for safety, biological activity of tofersen; phase 3 trial underway.News Release January 6, 2020 Miller receives international innovation prizeRecognized for developing experimental treatment for ALS.National Leaders August 15, 2019 Antisense drugs for Huntington’s, ALS and prion diseases could meet the dire need for brain treatmentsSource: Scientific American May 1, 2019 Experimental ALS treatment could be ‘game-changing’ for genetic ALSSource: CNN July 16, 2018 New ALS therapy in clinical trialsDrug extends survival, reverses some neuromuscular damage in animals.News Release May 7, 2018 Miller receives Essey award from neurological societyRecognized for advancing research into ALS.National Leaders Posts navigation 1 2 Next ›
